Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study
| Autor: | Haruhito Azuma, Akihiko Okuyama, Hironobu Akino, Hirotsugu Uemura, Yoji Katsuoka, Nobutaka Shimizu, Tatsuya Nakatani, Mikio Namiki, Hideki Fuse, Naoki Segawa, Yasuyoshi Fujiuchi, Teruo Inamoto, Akira Tsujimura, Satoshi Tamada, Yasuhide Kitagawa, Osamu Yokoyama, Naoki Oguchi, Hidenori Tsuji, Akihiko Watanabe, Tadashi Matsuda, Norio Nonomura |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Urology Anticholinergic Nocturnal urine volume urologic and male genital diseases Imidafenacin Cholinergic Antagonists law.invention Pharmacotherapy Randomized controlled trial Japan Lower Urinary Tract Symptoms Lower urinary tract symptoms law Surveys and Questionnaires Medicine Nocturia Humans Prospective Studies Prospective cohort study Aged Aged 80 and over Benign prostatic hyperplasia business.industry Overactive bladder Incidence Imidazoles medicine.disease female genital diseases and pregnancy complications Treatment Outcome Adrenergic alpha-1 Receptor Antagonists Quality of Life Original Article Drug Therapy Combination medicine.symptom business medicine.drug Half-Life |
| Zdroj: | World Journal of Urology |
| ISSN: | 1433-8726 0724-4983 |
| Popis: | Purpose To evaluate the efficacy and safety of imidafenacin (IM), a novel short half-life anticholinergic, as add-on therapy for male LUTS with nocturia and nocturnal polyuria. Materials and methods This multicenter, prospective, randomized, open-labelled study was conducted and involved men who had frequency, urgency, and nocturia despite receiving a stable dose of α1-blocker for ≥1 month. Subjects were randomised to control (α1-blocker alone), IM twice/day (α1-blocker +0.1 mg imidafenacin twice daily), or IM nightly (α1-blocker plus 0.1 mg imidafenacin nightly) group; the treatment period was 8 weeks. Primary endpoints included improvements in night-time frequency and Nocturia Quality of Life Questionnaire (N-QOL) scores. Secondary endpoints included changes from the baseline in frequency volume chart variables, and post-void residual volume. Results and limitations Compared with the controls, IM twice/day and IM nightly patients had a significantly lower night-time frequency (changes from baseline: 0.1 ± 0.8 in control, −0.6 ± 0.9 in IM twice/day, and −0.4 ± 1.0 in IM nightly, p = 0.5227, 0.0006 and 0.0143, respectively). The hours of undisturbed sleep and N-QOL score were significantly improved in IM twice/day group, though not IM nightly group. Nocturnal urine volume was significantly reduced in IM nightly group, although total urine volume remained unchanged. Conclusions A short half-life anticholinergic is suggested to be safe and effective as an add-on therapy for residual nocturia in patients with male LUTS receiving α1-blocker treatment. Anticholinergic administration nightly could reduce the nocturnal urine volume. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink